Weight-Based Dosing for HRZE in Tuberculosis

Standard Weight-Banded Dosing for Adults

The British Thoracic Society and American Thoracic Society recommend a weight-banded approach for daily dosing of isoniazid, rifampicin, pyrazinamide, and ethambutol, with specific milligram amounts assigned to weight ranges to ensure adequate drug exposure while minimizing toxicity risk 1, 3
For isoniazid, the recommended daily dose is 300 mg for adults, approximately 5 mg/kg, with a maximum dose of 300 mg for children, and 15 mg/kg three times weekly for intermittent dosing 1, 3
For rifampicin, the recommended daily dose is 450 mg for adults <50 kg and 600 mg for adults ≥50 kg, with a dose of 10 mg/kg daily for children, and 600 mg three times weekly for adults >50 kg for intermittent dosing 1
For pyrazinamide, the recommended daily dose is 1,000 mg for adults 40-55 kg, 1,500 mg for adults 56-75 kg, and 2,000 mg for adults 76-90 kg, with a maximum daily dose of 2,000 mg regardless of weight 2
For ethambutol, the recommended daily dose is 800 mg for adults 40-55 kg, 1,200 mg for adults 56-75 kg, and 1,600 mg for adults 76-90 kg, with a dose of 15-25 mg/kg daily for children 1, 3

Accurate calculation based on lean body weight is essential, particularly for ethambutol and pyrazinamide, to reduce toxicity risk and ensure adequate exposure, as emphasized by the CDC 1, 3
Patients at the upper end of a weight band should receive the higher dose to ensure adequate drug exposure and prevent treatment failure, as recommended by the American Thoracic Society 2

For twice-weekly directly observed therapy (DOT), higher doses are required, including isoniazid 15 mg/kg, rifampicin 600 mg for adults >50 kg, pyrazinamide 2,000-4,000 mg depending on weight, and ethambutol 2,000-4,000 mg depending on weight 1, 2, 3
For three times weekly dosing, the recommended doses are isoniazid 15 mg/kg, rifampicin 600 mg for adults >50 kg, pyrazinamide 1,500-3,000 mg depending on weight, and ethambutol 30 mg/kg 1, 2

HIV-infected patients with CD4 <100/μL should receive daily or three times weekly dosing, not twice weekly, due to higher treatment failure rates with less frequent dosing, as recommended by the American Thoracic Society 3

Never use simple mg/kg calculations without checking against weight-banded tables, as this can lead to underdosing or overdosing, as warned by the British Thoracic Society and American Thoracic Society 1, 2
Do not omit ethambutol in the initial phase unless drug susceptibility is confirmed and primary isoniazid resistance is <4% in the community, as recommended by the American Thoracic Society 5
Fixed-dose combination tablets may not provide adequate dosing for patients >90 kg, requiring additional individual drug tablets to achieve target doses, as noted by the American Thoracic Society 2
Pyrazinamide should not be continued beyond 2 months in drug-susceptible TB, even if extending total treatment duration, as prolonged use increases hepatotoxicity without additional benefit, as recommended by the American Thoracic Society 2, 4